- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03324945
Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients
Chemotherapy-Induced Cognitive Impairment in Patients With Ovarian Cancer: A Phase II Study of the Cognitive Effects of Platinum/Taxane-based Chemotherapy in Patients With Ovarian Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky Markey Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with any stage epithelial ovarian cancer, including cancers arising from the fallopian tube and primary peritoneal cancer, or patients with other gynecologic malignancy (any stage), who are chemotherapy-naïve, and scheduled to undergo at least 6 cycles of intravenous platinum/taxane-based chemotherapy.
- Patients must have adequate bone marrow, renal, hepatic, and sensory neurologic function to be eligible to receive platinum/taxane-based chemotherapy.
- Patients must have a World Health Organization Performance Status of ≤ 2.
- Age ≥18 years.
- Ability to understand and the willingness to sign an approved written informed consent document.
Exclusion Criteria:
- Patients who have received prior cytotoxic chemotherapy are ineligible. Patients may have received prior adjuvant hormonal therapy for localized breast cancer, provided that it was completed prior to registration, and that the patient remains free of recurrent or metastatic disease.
- Patients undergoing neoadjuvant chemotherapy with planned interval cytoreductive surgery and adjuvant therapy are not included in this group.
- Patients who are receiving any other investigational agents are excluded.
- Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic outcomes and other adverse events.
- With the exception of non-melanoma skin cancer and other specific malignancies noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this therapy are excluded.
- Patients with underlying dementia (or on medications to treat Alzheimer's disease such as donepezil, rivastigmine, galantamine, tacrine, or memantine), encephalopathy, or other neurological disorder known to adversely affect cognition (such as epilepsy or prior stroke) are excluded. (Patients with depression or anxiety are not excluded).
- Patients will be excluded from fMRI testing if they are left-handed, claustrophobic, have a pacemaker, or have metal implants. Patients not undergoing fMRI testing may still enroll in clinical trial, including the ERP testing, if all other eligibility criteria are met.
- Patients who are pregnant or nursing are excluded. Pregnant women are excluded from this study because cytotoxic chemotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cytotoxic chemotherapy, breastfeeding should be discontinued if the mother is treated with cytotoxic chemotherapy.
- Patients who are non-English speaking are excluded because of the inability to adequately administer neurocognitive testing in non-English languages.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Neurocognitive Assessment +/- FMRI
All participants receive pre- and post-chemotherapy neurocognitive assessments.
A sequentially-assigned subset also receive pre- and post-chemotherapy Functional Magnetic Resonance Imaging (FMRI) procedures.
|
Baseline and post-chemotherapy neurocognitive testing.
A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reliable Change Index (RCI)
Time Frame: 4 weeks after completing cycle #6 chemotherapy (each cycle is 21 days)
|
To address the primary aim, RCI (which is essentially a z-score) for each patient will be calculated from the pre-, post-chemotherapy Montreal Cognitive Assessment (MoCA) test results.
Then a Wilcoxon signed rank test will be applied to the RCI values with corresponding 95% confidence intervals.
|
4 weeks after completing cycle #6 chemotherapy (each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the correlation between biologic markers of oxidative stress and neurocognitive test results.
Time Frame: 4 weeks after completing cycle #6 chemotherapy (each cycle is 21 days)
|
Analysis of covariance (ANCOVA), adjusting for baseline log serum levels, will be utilized to assess for differences in log levels over timepoints including the 4 and 6 hour samples.
Spearman correlations will be utilized to describe associations with cognitive tests scores and biochemical measured in addition to Spearman Correlation coefficients between baseline biochemical measures.
|
4 weeks after completing cycle #6 chemotherapy (each cycle is 21 days)
|
Assess the correlation between brain imaging and neurocognitive test results
Time Frame: 4 weeks after completing cycle #6 chemotherapy (each cycle is 21 days)
|
For neurological outcomes, a longitudinal comparison before and after Chemotherapy in fMRI (percent signal change and extend of activation voxels), DTI (FA % change), and ERP (uV) will be performed. There will be changes in patterns of fMRI responses, FA, and ERP signals from baseline to after treatment. We expect that fMRI activation will be change in prefrontal regions change of effort needed to do the memory task. Changes in white matter FA in after the treatment may be observable in the white matter regions such as the frontal and temporal cortices as well as in gray matter regions suspected to be affected by the Chemo. Cognitive ERP patterns will be changed in the same individuals. fMRI and ERP analysis can be analyzed and compared at individual level. To explore correlations between fMRI outcomes and cognitive measures, ANCOVA is an appropriate choice since we want to study measures after treatment, relative to initial values. |
4 weeks after completing cycle #6 chemotherapy (each cycle is 21 days)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rachel W Miller, MD, University of Kentucky
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Female
- Neurocognitive Disorders
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Cognition Disorders
- Drug-Related Side Effects and Adverse Reactions
- Ovarian Neoplasms
- Cognitive Dysfunction
- Chemotherapy-Related Cognitive Impairment
Other Study ID Numbers
- MCC-15-GYN-333
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-induced Cognitive Impairment
-
University of AberdeenNHS GrampianRecruiting
-
Vanderbilt University Medical CenterUniversity of UtahCompletedCancer Survivors | Chemotherapy-related Cognitive ImpairmentUnited States
-
University Medicine GreifswaldUniversity of GreifswaldRecruitingBreast Cancer | Cognitive ImpairmentGermany
-
Jay F. Piccirillo, MDBarnes-Jewish Hospital; Washington University Siteman Cancer CenterCompleted
-
NYU Langone HealthCompletedBreast CancerUnited States
-
University of PittsburghNational Cancer Institute (NCI); National Institutes of Health (NIH)Recruiting
-
Vanderbilt University Medical CenterCompletedBreast Cancer | Chemotherapy-related Cognitive Impairment | Chemo Fog | Chemo Brain | ChemobrainUnited States
-
University of UtahActive, not recruiting
-
Vanderbilt University Medical CenterUniversity of UtahRecruitingChemotherapy-Related Cognitive Impairment | Chemo-brainUnited States
-
Posit Science CorporationCompletedBreast Cancer | Memory Disorders | Cognitive SymptomsUnited States
Clinical Trials on Neurocognitive assessments
-
University Health Network, TorontoRecruiting
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell UniversityActive, not recruitingGlioblastoma | Brain CancerUnited States
-
Memorial Sloan Kettering Cancer CenterDr. Susan Love Research Foundation; ENFORMIA INC.Active, not recruitingBreast Cancer SurvivorsUnited States
-
University of California, San DiegoRecruitingCarotid Artery Diseases | Neurocognitive DysfunctionUnited States
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Brown UniversityCompletedHIV | Alcohol Consumption | MotivationUnited States
-
Institut National de la Santé Et de la Recherche...University College, LondonCompletedHuntington Disease | White Matter AlterationsFrance
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)CompletedMood Disorders | Hypertension | Sleep | Overweight and Obesity | Vascular Stiffness | Elevated Blood PressureUnited States
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertension | Sleep | Prehypertension | Endothelial Dysfunction | Overweight and Obesity | Vascular Stiffness | Elevated Blood PressureUnited States
-
Centre Hospitalier Universitaire de NiceCompleted
-
National University Hospital, SingaporeRecruitingPostoperative Delirium | Hip FracturesSingapore, Japan, Korea, Republic of, Malaysia, Thailand